Divalproex Sodium Tablet, Delayed Release
Product Images NDC 57237-047

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 57237-047). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rising Pharma Holdings, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Divalproex Fig1)

A bar chart comparing percentages between placebo (PBO) and divalproex sodium delayed-release tablets (DVPX) in two studies. Study 1 shows 26% for placebo and 60% for DVPX using the YMRS scale. Study 2 shows 29% for placebo and 58% for DVPX using the MRS scale. An asterisk indicates statistical significance (p < 0.05).*

FDA Label Image

Figure 2 (Divalproex Fig2)

A line graph, titled Figure 2, comparing the percentage reduction in CPS rate against the percentage of patients for Divalproex Sodium delayed-release tablets versus placebo. The graph's y-axis represents percentage reduction in CPS rate from -100% to 100%, with improvement upward and worsening downward, while the x-axis shows the percentage of patients from 0 to 100%.*

FDA Label Image

Figure 3 (Divalproex Fig3)

A graph labeled Figure 3 showing the percentage reduction in CRS rate on the vertical axis and percentage of patients on the horizontal axis. It compares outcomes of patients receiving high dose versus low dose treatment, with high dose represented by a solid line and low dose by a dotted line. The vertical axis indicates improvement and worsening directions.*

FDA Label Image

Figure 4 (Divalproex Fig4)

Bar chart titled 'Figure 4 Mean 4-week Migraine Rates' comparing migraine rates between placebo and Divalproex Sodium delayed-release tablets from two studies. The vertical axis shows migraine rates from 0 to 6. In both Study 1 and Study 2, bars indicate lower migraine rates with Divalproex Sodium delayed-release tablets compared to placebo. Footnotes specify dosing for Study 1 as 1,087 mg/day and Study 2 as 500 or 1,000 mg/day.*

FDA Label Image

Package Label-principal Display Panel (125 mg (100 Tablets Bottle))

Label for Divalproex Sodium Delayed-Release Tablets USP, 125 mg Valproic Acid Activity, from Rising Pharma Holdings, Inc. The label indicates 100 tablets per container, prescription only, and includes storage instructions, distribution information by Rising Health, LLC, and a barcode. The label also notes the medication guide instructions for pharmacists and a revision date of 11/2017.*

FDA Label Image

Package Label-principal Display Panel (250 mg (100 Tablets Bottle))

Label for Divalproex Sodium Delayed-Release Tablets, USP 250 mg valproic acid activity, supplied by Rising Pharma Holdings, Inc. The label indicates 100 tablets, prescription only, with storage instructions and distributor information for Rising Health, LLC, Saddle Brook, NJ. The product is made in India.*

FDA Label Image

Package Label-principal Display Panel (500 mg (100 Tablets Bottle))

Label for Divalproex Sodium Delayed-Release Tablets, USP, 500 mg valproic acid activity, tablets count 100. The label states the product is for prescription use only (Rx only) and includes storage instructions. Distributed by Rising Health, LLC, made in India, with NDC 57237-048-01 and distributed by Rising Pharma Holdings, Inc.*

FDA Label Image

Chemical Structure (Divalproex Str)

Chemical structure of divalproex sodium showing the molecular arrangement including sodium ion and associated organic groups in the polymer chain notation.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.